Latest Non-steroidal anti-inflammatory drugs Stories

Inflammation has a role in heart disease and may also be implicated in aging brain Daily low dose aspirin could slow the decline in brain power among elderly women at high risk of heart disease, indicates observational research published in the online journal BMJ Open. The researchers base their findings on 681 women between the ages of 70 and 92, 601 of whom were at high risk of heart disease and stroke, defined as a 10% or greater risk on a validated risk scale (Framingham). All...

DEERFIELD, Ill., Oct. 1, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has completed the expansion of its sales force from 80 to 150 representatives. This expansion will allow increased reach and frequency of calls on physician targets for its lead product DUEXIS(®) (ibuprofen and famotidine), which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper...

DEERFIELD, Ill., Sept. 28, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP), announced today that it has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/403,930 and U.S. Application Serial No. 13/403,923 both entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS(®) (ibuprofen and famotidine) tablets. DUEXIS is indicated for the relief of signs and symptoms...

SOLANA BEACH, Calif., Sept. 19, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:OTCQB) today announced the initiation of a clinical study of Impracor(TM), a topical cream that delivers a dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study will measure the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different "real world' conditions, including normal...

NASHVILLE, Tenn., Sept. 19, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced top-line results from a clinical pediatric pain study evaluating the safety and analgesic efficacy of Caldolor(TM) (ibuprofen) Injection in treating pain in tonsillectomy patients ranging from 6 to 16 years old. When administered prior to surgery, Caldolor use was associated with a statistically significant reduction in the number of post-operative narcotic doses...

April Flowers for redOrbit.com - Your Universe Online If you are like most Americans, there is a bottle of pain relievers somewhere close by your desk as you read this. Whether to treat a headache, back ache, or sore muscles, at the first sign of pain most of us are popping some sort of analgesic in our mouth. They are the most frequently used medications in the U.S. The problem is, popping that pill might help your pain, but it might hurt your hearing. According to new research...

Lee Rannals for redOrbit.com – Your Universe Online Taking painkillers increases your risk of death if you are a heart attack survivor, according to a study published in the journal Circulation. Scientists found that those heart attack survivors who take painkillers not only increased their chances of having a second heart attack, but also increased their risk of dying. Over-the-counter painkillers like ibuprofen and naproxen, as well as prescription drugs like Celebrex, are the...

MISSISSAUGA, ON, Sept. 5, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the United States Patent Office has issued United States Patent # 8,252,838 relating to compositions and methods of using PENNSAID(®) (diclofenac sodium topical solution) 2.0% w/w (PENNSAID 2% Patent).  The patent expires on April 21, 2028. Nuvo's U.S. licensing...

Daily aspirin usage is associated with lower overall cancer mortality, but the association may be smaller than what was previously believed, according to a study published August 10 in the Journal of the National Cancer Institute. A recent pooled analysis of randomized trials looking at the effects of daily aspirin use as a preventive measure for vascular events found a significant decrease in overall cancer mortality, of 37%, during a 5-year follow-up analysis, and 15% during a ten-year...

redOrbit Staff & Wire Reports Taking a daily dose of aspirin can help fight off stomach, esophageal or colorectal cancer, claims a new study published in the latest edition of the Journal of the National Cancer Institute. In a study of more than 100,000 healthy individuals who were placed on a daily low-dose aspirin regiment, researchers with the American Cancer Society in Atlanta discovered that the painkilling drug can reduce the risk of developing cancer and slow the spread of...